Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy
BACKGROUND: Ductal adenocarcinoma of the pancreas (PDAC) remains one of the most lethal malignancies. To date, no guidelines exists for isolated resectable metachronous disease. It is still unknown, which patients may benefit from relapse surgery. The aim of our study was to compare disease free survival (DFS) and post relapse survival (PRS) in patients with isolated local recurrence, metachronous hepatic or pulmonary metastases.
METHODS: Patients with isolated resectable local recurrence, metachronous hepatic or pulmonary metastases were included for survival analyses. PRS of surgically treated patients (local (n = 11), hepatic (n = 6) and pulmonary metastases (n = 9)) was compared to conservatively treated patients (local (n = 17), hepatic (n = 37) and pulmonary metastases (n = 8)).
RESULTS: Resected PDAC patients suffering from isolated metachronous hepatic metastases initially had a higher T-stage and venous invasion (V1) compared to the other patients. DFS in the metachronous pulmonary metastases group was longer compared to DFS of the hepatic metastases and local recurrence groups. Surgical resection significantly improved PRS in patients with local recurrence and pulmonary metastases, when compared to patients receiving chemotherapy alone. Very-long term survivors (> 5 years) were detected following secondary resection of local recurrence and 45% of these patients were still alive at the end of our study period.
CONCLUSION: Although DFS in PDAC patients suffering from isolated local recurrence was dismal and comparable to that of patients with isolated hepatic metastases, very-long term survivors were present only in this group. These results indicate that a surgical approach for isolated local recurrence, if anatomically possible, should be considered.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
BMC surgery - 21(2021), 1 vom: 03. März, Seite 110 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Safi, S A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ductal adenocarcinoma of the pancreas |
|---|
| Anmerkungen: |
Date Completed 05.03.2021 Date Revised 04.06.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12893-021-01082-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322154812 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322154812 | ||
| 003 | DE-627 | ||
| 005 | 20231225181431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12893-021-01082-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1073.xml |
| 035 | |a (DE-627)NLM322154812 | ||
| 035 | |a (NLM)33658016 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Safi, S A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2021 | ||
| 500 | |a Date Revised 04.06.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Ductal adenocarcinoma of the pancreas (PDAC) remains one of the most lethal malignancies. To date, no guidelines exists for isolated resectable metachronous disease. It is still unknown, which patients may benefit from relapse surgery. The aim of our study was to compare disease free survival (DFS) and post relapse survival (PRS) in patients with isolated local recurrence, metachronous hepatic or pulmonary metastases | ||
| 520 | |a METHODS: Patients with isolated resectable local recurrence, metachronous hepatic or pulmonary metastases were included for survival analyses. PRS of surgically treated patients (local (n = 11), hepatic (n = 6) and pulmonary metastases (n = 9)) was compared to conservatively treated patients (local (n = 17), hepatic (n = 37) and pulmonary metastases (n = 8)) | ||
| 520 | |a RESULTS: Resected PDAC patients suffering from isolated metachronous hepatic metastases initially had a higher T-stage and venous invasion (V1) compared to the other patients. DFS in the metachronous pulmonary metastases group was longer compared to DFS of the hepatic metastases and local recurrence groups. Surgical resection significantly improved PRS in patients with local recurrence and pulmonary metastases, when compared to patients receiving chemotherapy alone. Very-long term survivors (> 5 years) were detected following secondary resection of local recurrence and 45% of these patients were still alive at the end of our study period | ||
| 520 | |a CONCLUSION: Although DFS in PDAC patients suffering from isolated local recurrence was dismal and comparable to that of patients with isolated hepatic metastases, very-long term survivors were present only in this group. These results indicate that a surgical approach for isolated local recurrence, if anatomically possible, should be considered | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Ductal adenocarcinoma of the pancreas | |
| 650 | 4 | |a Hepatic metastases | |
| 650 | 4 | |a Local recurrence | |
| 650 | 4 | |a Oligometastatic | |
| 650 | 4 | |a PDAC | |
| 650 | 4 | |a Pulmonary metastases | |
| 650 | 4 | |a Survival outcome | |
| 700 | 1 | |a Lehwald-Tywuschik, N |e verfasserin |4 aut | |
| 700 | 1 | |a Rehders, A |e verfasserin |4 aut | |
| 700 | 1 | |a Fluegen, G |e verfasserin |4 aut | |
| 700 | 1 | |a Haeberle, L |e verfasserin |4 aut | |
| 700 | 1 | |a Keitel, V |e verfasserin |4 aut | |
| 700 | 1 | |a Knoefel, W T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC surgery |d 2001 |g 21(2021), 1 vom: 03. März, Seite 110 |w (DE-627)NLM112747434 |x 1471-2482 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:1 |g day:03 |g month:03 |g pages:110 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12893-021-01082-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 1 |b 03 |c 03 |h 110 | ||